• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.03% Nasdaq Up1.29%

    AVEO Pharmaceuticals, Inc. (AVEO)

    1.51 Down 0.01(0.66%) May 1, 4:00PM EDT
    |After Hours : 1.51 0.00 (0.00%) May 1, 4:10PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    AVEO Pharmaceuticals, Inc.
    650 East Kendall Street
    Cambridge, MA 02142
    United States - Map
    Phone: 617-299-5000
    Website: http://www.aveopharma.com

    Index Membership:N/A
    Full Time Employees:57

    Business Summary 

    AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. The company’s development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on AVEO Pharmaceuticals, Inc.

    Corporate Governance 
    AVEO Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Michael P. Bailey , 50
    Chief Exec. Officer, Pres, Sec. and Director
    Dr. Jeno Gyuris Ph.D., 55
    Exec. Officer
    Mr. David B. Johnston , 60
    Chief Financial Officer
    Mr. Keith S. Ehrlich CPA, 64
    Chief Financial Officer
    Dr. Emile Farhan Ph.D.,
    VP of Technical Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders